Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion - simplywall.st

AI-generated analysis

🔬 Bristol-Myers Squibb expanded its kidney cancer trial (ROSETTA RCC-208) via a collaboration with Arcus Biosciences to include new casdatifan arms.

💰 The stock trades at $56.24, offering a 4.5% dividend yield and a value score of 4.

📉 Analysts forecast annual revenue decreases of 6.2% over the next three years.

📈 Profit margins are projected to rise from 15.0% currently to 21.5% in three years.

💵 A widely followed valuation model estimates a fair value of $62.96, implying a 10.7% undervaluation.

⚠️ The company faces risks from upcoming patent expiries on key drugs and potential underperformance of new launches.

📊 The current P/E ratio of 15.8x is higher than the industry average (15.1x) but lower than peers (22.3x).

Bullish Signals
  • The company has secured a clinical collaboration with Arcus Biosciences to expand its kidney cancer trial, signaling continued pipeline development.
  • Analysts forecast a significant improvement in profit margins, rising from 15.0% to 21.5% over the next three years.
  • Valuation models suggest the stock is undervalued by 10.7% with a fair value target of $62.96 versus the current price of $56.24.
  • The stock offers an attractive 4.5% dividend yield, providing income support for investors.
Risk Factors
  • Analysts project that revenue will decrease by 6.2% annually over the next three years.
  • The company faces real pressure from upcoming patent expiries on its key drugs.
  • There is a risk that newer launches and pipeline assets could underperform market expectations.
Full Analysis
Bristol-Myers Squibb (BMY) stock is currently trading at $56.24, reflecting a mixed performance with a year-to-date return of 5.2% and a recent 90-day decline of 5.81%. The company has recently expanded its kidney cancer trial, the ROSETTA RCC-208 study, through a clinical collaboration with Arcus Biosciences to add new casdatifan arms. Analysts project that BMY's revenue will decrease by 6.2% annually over the next three years, while profit margins are expected to improve significantly from 15.0% today to 21.5% in three years. Based on these assumptions regarding earnings paths and future multiples, a popular valuation narrative suggests a fair value of $62.96, indicating the stock is undervalued by approximately 10.7%. Despite the optimistic valuation outlook, the company faces headwinds including upcoming patent expiries on key drugs and the risk that new launches or pipeline assets may underperform expectations. The current P/E ratio of 15.8x sits between the US pharmaceutical industry average of 15.1x and peer group average of 22.3x, suggesting a complex valuation landscape with both risks and opportunities.